Publications
Publications
Show Results For
- All HBS Web
(1,287)
- Faculty Publications (521)
- February 1995 (Revised March 1995)
- Teaching Note
Astra/Merck Group TN
Teaching Note for (9-594-045). View Details
Keywords: Pharmaceutical Industry
- January 1995 (Revised November 2021)
- Case
Portfolio Planning at Ciba-Geigy and the Newport Investment Proposal
By: David J. Collis and Elizabeth Wynne Johnson
Covers the history of portfolio planning at CIBA-GEIGY, a leading Swiss chemical and pharmaceutical company, beginning with the introduction of the process in the mid-1980s. The discussion extends to the application of portfolio planning techniques to a specific... View Details
- December 1994 (Revised March 1996)
- Case
Ciba Consumer Pharmaceuticals' Acutrim: Challenges and Opportunities in Today's Diet Industry
By: Nancy F. Koehn and Rebecca Voorheis
Since its introduction in 1983, Acutrim has been a major player in the U.S. appetite suppressant market and in the broader diet industry. This case focuses on the strategic, regulatory, marketing, and financial challenges this product and the rapidly changing diet... View Details
- August 1994
- Teaching Note
Yamanouchi Pharmaceutical Co., Ltd. TN
By: Robin Cooper and Robert S. Kaplan
Keywords: Pharmaceutical Industry
- March 1994 (Revised March 1995)
- Case
Astra/Merck Group
By: Frank V. Cespedes and Marie Bell
Astra/Merck (A/M), originally a joint venture of AB Astra and Merck & Co., is preparing to be an independent company in 1993. Since the company does not engage in basic research and development of drugs, it is essentially a distribution organization. Fundamental to... View Details
- March 1994 (Revised April 1994)
- Case
Eli Lilly and Co.: The Flexible Facility Decision--1993
By: Gary P. Pisano
In 1993, Eli Lilly is preparing to build manufacturing capacity for three new pharmaceutical products that it expects to launch in 1996. Management wrestles with a decision of whether to add specialized manufacturing capacity or flexible capacity. This question touches... View Details
- January 1994 (Revised July 1998)
- Case
Repligen Corporation: January 1992
By: Josh Lerner and David Kane
Sandford Smith, CEO of Repligen, faces the breakdown of negotiations about a proposed joint venture with a large pharmaceutical firm. He must decide whether to proceed using his firm's internal resources or whether to seek to revise the proposed collaboration. If the... View Details
- October 1993 (Revised February 1995)
- Case
Dendrite International
By: Frank V. Cespedes and Marie Bell
Dendrite International is a $23 million (1992 revenues) supplier of sales automation software to pharmaceuticals companies in Europe, Japan, and the United States. The firm's strategy has depended on being a full-service supplier to multinational firms. Impending... View Details
- September 1993
- Case
Manufacturing at ALZA: The Right Prescription? (A)
ALZA, a company specializing in drug delivery systems such as transdermal patches, considers manufacturing its own products. Until now, the company has conducted research and development on its patented system but has then licensed the technology to client-partner... View Details
- September 1993
- Supplement
Manufacturing at ALZA: The Right Prescription? (B)
ALZA, a drug delivery company, must decide what and for whom to manufacture. In the past, it has licensed to pharmaceutical companies its patented system for the slow release of drugs into the human system. Therefore the company has little experience in choice of drug... View Details
- September 1993
- Supplement
Manufacturing at ALZA: The Right Prescription? (C)
ALZA, a drug delivery company, considers marketing its own and other companies' products. The primary issue is whether to build an internal sales force focused on a few niche markets, to finance a sales force through alliances, or to acquire a marketing company. View Details
- March 1993 (Revised September 1995)
- Teaching Note
Note on Pharmaceutical Industry Regulation TN
Teaching Note for (9-792-002). View Details
- March 1993 (Revised May 1998)
- Teaching Note
ImmuLogic Pharmaceutical Corporation (Series) TN
By: Josh Lerner
Teaching Note for (9-293-066--071) and (9-293-087). View Details
Keywords: Pharmaceutical Industry
- March 1993
- Supplement
Burroughs Wellcome and AZT (B)
Describes Burroughs Wellcome's response to protests over the pricing of its AIDS drug AZT in September 1989. Also presents short-term reactions by government officials, AIDS activists, and investors to Burroughs Wellcome's strategy. View Details
- March 1993
- Supplement
Burroughs Wellcome and AZT (C)
Describes key developments relating to Burroughs Wellcome, AZT and other AIDS drugs, and the AIDS issue in general from late 1989 through 1992. Includes excerpts from Wellcome PLC's financial statements and updated statistics on AIDS in the United States. View Details
- February 1993 (Revised August 1995)
- Case
Medicare Payment for Drugs and Medical Devices
- January 1993 (Revised November 1993)
- Case
Warner-Lambert Ireland: Niconil
By: John A. Quelch and Susan Smith
The marketing director of Warner-Lambert's Irish subsidiary is completing the marketing plan for the launch of Niconil, a transdermal skin patch to facilitate smoking cessation. View Details